EGFR and non-small cell lung carcinoma: Substantial advancements have been made in the first-line treatment of advanced EGFR-mutant NSCLC, particularly with the development of 3rd-G TKIs, as demonstrated by studies such as FLAURA (Soria et al., 2018), FLAURA China (Cheng et al., 2021), FURLONG (Shi et al., 2022), AENEAS (Lu et al., 2022) and LASER301 (Cho et al., 2023).